Breyanzi, Camzyos and Reblozyl generated $1.28 billion in Q1 sales for Bristol-Myers Squibb, up 42.2% year-over-year, positioning full-year revenue and EPS at the upper end of guidance. The company holds royalty rights to Kardigan’s late-stage cardiology candidates—danicamtiv in Phase IIb/III, ataciguat in mid-stage and tonlamarsen in Phase IIb—through its in-licensing agreements.
Breyanzi, Camzyos and Reblozyl combined for $1.28 billion in Q1 sales, marking a 42.2% increase year-over-year and driving Bristol-Myers Squibb toward the upper end of its 2026 revenue and EPS guidance.
Under its in-licensing deals with MyoKardia and ARCH Venture Partners, Bristol-Myers Squibb retains royalty rights on three cardiovascular candidates in Kardigan’s pipeline, creating a potential new revenue stream as the company advances toward an IPO.
Danicamtiv is in Phase IIb/III trials targeting genetic dilated cardiomyopathy, ataciguat is in mid-stage studies for moderate calcific aortic valve stenosis, and tonlamarsen is in Phase IIb development for severe hypertension; approval milestones could trigger significant payouts.
Barrons
